Grégory Verdeil

List of Publications by Year
in descending order

37 papers	**2,031** citations	304743 **22** h-index	395702 **33** g-index
39 all docs	**39** docs citations	**39** times ranked	**4254** citing authors

#	Article	IF	Citations
1	*Helicobacter pylori* infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut, 2022, 71, 457-466.	12.1	87
2	c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells. EMBO Journal, 2022, 41, e109300.	7.8	10
3	Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy. Cancers, 2021, 13, 4712.	3.7	29
4	Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients. OncoImmunology, 2021, 10, 1873585.	4.6	15
5	Severe COVID-19 patients exhibit an ILC2 NKG2D+ population in their impaired ILC compartment. Cellular and Molecular Immunology, 2021, 18, 484-486.	10.5	41
6	Murine CD8 T-cell functional avidity is stable in vivo but not in vitro: Independence from homologous prime/boost time interval and antigen density. European Journal of Immunology, 2020, 50, 505-514.	2.9	6
7	CD40 Agonist Restores the Antitumor Efficacy of Anti-PD1 Therapy in Muscle-Invasive Bladder Cancer in an IFN I/II-Mediated Manner. Cancer Immunology Research, 2020, 8, 1180-1192.	3.4	19
8	c-MAF, a Swiss Army Knife for Tolerance in Lymphocytes. Frontiers in Immunology, 2020, 11, 206.	4.8	39
9	LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. OncoImmunology, 2020, 9, 1736792.	4.6	36
10	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
11	Maf deficiency in T cells dysregulates Treg - TH17 balance leading to spontaneous colitis. Scientific Reports, 2019, 9, 6135.	3.3	25
12	Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy. Cancers, 2019, 11, 1832.	3.7	38
13	More T Cells versus Better T Cells in Patients with Breast Cancer. Cancer Discovery, 2017, 7, 1062-1064.	9.4	6
14	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175
15	Peripheral Deletion of CD8 T Cells Requires p38 MAPK in Cross-Presenting Dendritic Cells. Journal of Immunology, 2017, 199, 2713-2720.	0.8	0
16	Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca^{2+} signalling and granule mobilization. Immunology, 2017, 150, 199-212.	4.4	3
17	Very Late Antigen-1 Marks Functional Tumor-Resident CD8 T Cells and Correlates with Survival of Melanoma Patients. Frontiers in Immunology, 2016, 7, 573.	4.8	73
18	Regulatory circuits of T cell function in cancer. Nature Reviews Immunology, 2016, 16, 599-611.	22.7	445

#	ARTICLE	IF	CITATIONS
19	*MAF* drives CD8$^+$ T-cell exhaustion. OncoImmunology, 2016, 5, e1082707.	4.6	3
20	From T cell "exhaustion" to anti-cancer immunity. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 49-57.	7.4	18
21	Molecular profiling of CD8 T cells in autochthonous melanoma identifies *Maf* as driver of exhaustion. EMBO Journal, 2015, 34, 2042-2058.	7.8	100
22	Inhibitory Receptors Beyond T Cell Exhaustion. Frontiers in Immunology, 2015, 6, 310.	4.8	188
23	29th Annual meeting of the Society for Immunotherapy of Cancer (SITC). , 2015, 3, .		9
24	Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8$^+$ T-cell therapy. OncoImmunology, 2014, 3, e958951.	4.6	4
25	Contribution of TCR Signaling Strength to CD8+ T Cell Peripheral Tolerance Mechanisms. Journal of Immunology, 2014, 193, 3409-3416.	0.8	28
26	The tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20) imposes a brake on antitumor activity of CD8 T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11115-11120.	7.1	79
27	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?. Pigment Cell and Melanoma Research, 2013, 26, 167-175.	3.3	9
28	Active STAT5 Regulates T-bet and Eomesodermin Expression in CD8 T Cells and Imprints a T-bet–Dependent Tc1 Program with Repressed IL-6/TGF-β1 Signaling. Journal of Immunology, 2013, 191, 3712-3724.	0.8	49
29	Activated STAT5 Promotes Long-Lived Cytotoxic CD8+ T Cells That Induce Regression of Autochthonous Melanoma. Cancer Research, 2012, 72, 76-87.	0.9	36
30	Epithelial-Mesenchymal-Transition-Like and TGFβ Pathways Associated with Autochthonous Inflammatory Melanoma Development in Mice. PLoS ONE, 2012, 7, e49419.	2.5	34
31	Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16683-16688.	7.1	46
32	Using gamma-cytokine complexes to improve antigen specific CD8 T cell responses in tumor-bearing mice. FASEB Journal, 2008, 22, 1076.3.	0.5	0
33	CD8 T Cell Help for Innate Antitumor Immunity. Journal of Immunology, 2007, 179, 6651-6662.	0.8	94
34	Temporal cross-talk between TCR and STAT signals for CD8 T cell effector differentiation. European Journal of Immunology, 2006, 36, 3090-3100.	2.9	23
35	STAT5-Mediated Signals Sustain a TCR-Initiated Gene Expression Program toward Differentiation of CD8 T Cell Effectors. Journal of Immunology, 2006, 176, 4834-4842.	0.8	72
36	Distinct Thresholds for CD8 T Cell Activation Lead to Functional Heterogeneity: CD8 T Cell Priming Can Occur Independently of Cell Division. Journal of Immunology, 2003, 170, 2442-2448.	0.8	49

#	ARTICLE	IF	CITATIONS
37	Gene Profiling Approach to Establish the Molecular Bases for Partial versus Full Activation of NaÃ¯ve CD8 T Lymphocytes. Annals of the New York Academy of Sciences, 2002, 975, 68-76.	3.8	23